Mushroom Triterpenes and Ganoderic Acids
57.9%
A 2017 analysis of 19 commercial Ganoderma supplements from the US market found that triterpenes — the compounds behind Reishi's most-studied health properties — were undetectable in more than half of the products tested.
Wu et al., Scientific Reports, 2017
495 distinct compounds
triterpenoids catalogued from 25 Ganoderma species since 1984 (Galappaththi et al., Biomolecules, 2022)
Ganoderic acid A
most-studied individual ganoderic acid — active across 8+ organ systems with 5 confirmed molecular targets (Sui et al., 2025)
2026 meta-analysis
first PROSPERO-registered systematic review + meta-analysis of Ganoderma triterpene anti-inflammatory evidence
Wu et al., Scientific Reports, 2017
View as image ↗Ganoderma lucidum, the mushroom known in China as Ling Zhi and in Japan as Reishi, has been documented in Chinese medicine texts for roughly 2,000 years. Among the first detailed scientific investigations of what makes it biochemically unusual was a 2006 review by Paterson, which described Reishi as a "therapeutic fungal biofactory" — a single organism capable of producing an unusual breadth and density of biologically active compounds.[1] The ganoderic acids, a class of bitter lanostane triterpene compounds found only in the Ganoderma genus, are the most studied of those compounds.
Ganoderic acids give Reishi its characteristic bitter taste and are associated with its anti-inflammatory, hepatoprotective, and anti-cancer effects in preclinical research. They are distinct from the beta-glucans that account for the immune-stimulating properties discussed in What Are Beta-Glucans? The Most Important Compound in Medicinal Mushrooms. The two compound classes act through different mechanisms, require different extraction methods, and are found in different concentrations depending on how the mushroom was grown and processed.
This distinction matters for buyers: a supplement standardized only for beta-glucans may have no meaningful ganoderic acid content. And as a 2017 quality audit of the US market revealed, more than half of commercial Reishi supplements tested had no detectable triterpenes at all.
Key Takeaways
- Ganoderic acids are oxygenated C30 lanostane-type triterpenoids found only in the Ganoderma genus; over 150 named variants have been characterized from G. lucidum, with 495 total triterpenoids catalogued across 25 Ganoderma species (Galappaththi et al., 2022)
- The most-studied individual compound, ganoderic acid A, shows anti-inflammatory, antitumor, hepatoprotective, cardiovascular, neuroprotective, renal, and lung-protective effects in preclinical research — with 5 molecular docking-confirmed targets including MAPK3, TNF, caspase-3, PPARγ, and β-catenin (Sui et al., 2025)
- Ganoderic acids act through direct NF-κB and AP-1 suppression — a different mechanism from beta-glucans, which activate immune cells via Dectin-1/TLR pattern recognition receptors (Dudhgaonkar et al., 2009)
- The most concentrated source of ganoderic acids per gram is not the fruiting body but the spore powder — though spores require sporoderm-breaking treatment to release their bioactives (Soccol et al., 2016; Wang et al., 2017)
- A 2017 analysis of 19 US commercial Ganoderma supplements found that triterpenes were detectable in only 8 products (42.1%) — 57.9% had no measurable triterpene content (Wu et al., 2017)
- Ganoderic acids are fat-soluble and require alcohol extraction; hot-water extraction produces a product with beta-glucans but no ganoderic acids (Ren et al., 2025)
What Ganoderic Acids Are: The 40-Word Definition
Ganoderic acids are oxygenated C30 lanostane-type triterpenoids exclusive to the Ganoderma genus. First identified in 1982, over 150 distinct variants have been characterized from Ganoderma lucidum alone. They share a tetracyclic ring structure derived from lanosterol via the mevalonate pathway, give Reishi its distinctive bitter taste, and are the primary compounds responsible for its anti-inflammatory, hepatoprotective, and anti-cancer properties in research.
The "C30" refers to the 30-carbon skeleton that all lanostane triterpenes share. "Oxygenated" means most ganoderic acid variants have oxygen-containing groups (hydroxyl groups, ketone groups, or both) attached to that skeleton at various positions. These oxygen attachments are what distinguishes one ganoderic acid variant from another, and what determines each variant's specific biological activity. The same underlying scaffold, modified at different positions, produces a compound library with dozens of distinct pharmacological profiles.
The bitter taste is a direct consequence of this chemistry. Ganoderic acids interact with human bitter taste receptors (TAS2R class) at the back of the throat. The taste evolved as a chemical deterrent against insects and other organisms that might consume the mushroom, and it has been recognized and documented in TCM texts for centuries before the molecular explanation was worked out.
495 Compounds From 25 Species: The Full Scope of Ganoderma's Chemical Factory
The Paterson 2006 review that introduced the "biofactory" concept documented more than 140 distinct triterpenoids from Ganoderma lucidum as of that date.[1] The count has grown substantially since then. A 2022 comprehensive review by Galappaththi and colleagues catalogued 495 distinct triterpenoid compounds from 25 Ganoderma species across 38 years of published research (1984–2022).[2]
The 495 compounds are organized into seven structural subclasses based on their carbon skeleton size: C31 (31-carbon chain), C30 (the classic lanostane types that predominate), C29, C27, C25, C24, and rearranged types where the lanostane ring system has been modified. The C30 lanostane-types are by far the most common and most studied. Within the C30 class, further classification comes from where the double bonds are located in the four-ring system: the 8,9-ene types (double bond between carbons 8 and 9), 8,9-dihydro types, and several other variants.
This structural diversity is not arbitrary. It reflects the ecological role these compounds play in the mushroom's survival. Reishi grows on dead or dying hardwood trees, and its chemical factory produces different compound variants under different environmental stresses, insect pressures, and substrate conditions. Different growing conditions produce different ganoderic acid profiles, which is one reason why growing substrate and harvest timing affect the potency of Reishi preparations.
Not all 495 compounds have been individually tested for pharmacological activity. Galappaththi's review included biological activity data where available, identifying specific compounds with notable profiles: ganoderic acid DM inhibited the enzyme 5α-reductase (implicated in hair loss and prostate enlargement) at 10.6 μM, outperforming the standard comparison by an order of magnitude; ganodermanontriol showed cancer cell growth inhibition at an IC50 of 5.8 μM in MCF-7 breast cancer cells.[2]
Ganoderic Acid A: The Most-Studied Individual Compound
Of the hundreds of ganoderic acid variants characterized, ganoderic acid A (GA-A) has received the most individual scientific attention. A 2025 in-depth review by Sui and colleagues in the Journal of Ethnopharmacology compiled the full pharmacological profile of GA-A across a decade of research.[4]
The breadth of effects attributed to GA-A in preclinical research is unusual even by the standard of well-studied natural compounds. The Sui 2025 review documents anti-inflammatory, antioxidant, antitumor, neuropsychopharmacological, hepatoprotective, cardiovascular, renal-protective, and lung-protective effects. Molecular docking analysis confirmed binding at five specific protein targets: MAPK3 (a kinase involved in cellular stress responses), TNF (a major inflammatory signaling protein), caspase-3 (a protein that triggers programmed cell death), PPARγ (a nuclear receptor regulating fat metabolism and inflammation), and β-catenin (a protein involved in cell growth signaling).
The multi-target profile is characteristic of many natural compounds, but GA-A's binding evidence is stronger than most because molecular docking studies have gone beyond identifying binding to predicting the geometry of those interactions. This does not mean GA-A has been proven to produce these effects in humans — the vast majority of evidence is from cell-culture and animal experiments. But it does establish biological plausibility for multiple mechanisms operating simultaneously.
A 2025 review by Sarkar and colleagues, covering Reishi's pharmacology in the context of its TCM history, makes an important practical note: ganoderic acid content is substantially lower in mycelium than in fruiting bodies.[3] Supplements derived from mycelium grown on grain substrates, a common commercial production method, will have dramatically lower ganoderic acid concentrations than those derived from mature fruiting bodies or properly processed spores.
What the Evidence Suggests Ganoderic Acids Do
Anti-Inflammatory Action: Different Mechanism Than Beta-Glucans
The clearest mechanistic distinction between ganoderic acids and beta-glucans is how they suppress inflammation.
Beta-glucans activate immune cells by binding to pattern recognition receptors on the cell surface, triggering an immune response cascade. Ganoderic acids work differently: they suppress inflammatory signaling from inside cells, directly blocking the two key transcription factors that switch on inflammatory gene expression, NF-κB and AP-1.
Dudhgaonkar and colleagues demonstrated this in 2009, isolating triterpenes from Ganoderma and testing them in cell-culture inflammatory models.[5] The isolated triterpenes suppressed both NF-κB and AP-1 activation. This NF-κB suppression is direct and does not require prior immune activation — it is a quieting mechanism rather than a stimulating one. This mechanistic distinction matters because a product's beta-glucan content says nothing about its triterpene content; the two compound classes need separate measurement and separate assessment.
A 2026 systematic review and meta-analysis published in Pharmaceuticals (MDPI) is the highest-quality current synthesis of the anti-inflammatory evidence for Ganoderma triterpenes specifically.[12] Registered with PROSPERO (CRD42024510982) and covering PubMed, Medline, and Embase through 2025, it found consistent evidence of potent anti-inflammatory activity across the preclinical literature. The reviewers called for clinical translation research addressing compound synergism, bioavailability, and long-term safety — appropriate scientific caution given that the evidence base is still largely preclinical.
Anti-Cancer Effects in Preclinical Research
A five-year review by Wang and colleagues covering ganoderic acid research from 2020 to 2024 catalogued anti-cancer activity for ganoderic acid variants against liver, prostate, breast, and gastric cancer cells.[6] The mechanisms are diverse: GA-A acts through the MAPK3/TNF/CASP3/PPARG/β-catenin pathways per network pharmacology analysis; other variants work through different cellular targets.
A 2005 study by Stanley and colleagues provided an early mechanistic window into how ganoderic acid-rich Reishi extract acts on cancer cells: it suppressed the secretion of VEGF and TGF-β1 from prostate cancer cells.[7] VEGF is the primary protein that tumors secrete to stimulate new blood vessel formation (angiogenesis), which is necessary for tumor growth. By reducing VEGF secretion, Ganoderma triterpenes may reduce a tumor's ability to recruit its own blood supply. This mechanism is separate from direct cell killing and is distinct from anything beta-glucans do.
All of this evidence is preclinical. Clinical trials in humans for ganoderic acid anticancer effects are limited. The preclinical data establishes mechanisms and provides rationale for further research, but it does not establish that consuming Reishi supplements will prevent or treat cancer in humans.
Hepatoprotective Effects
The TCM reputation of Reishi for liver protection has a molecular basis in ganoderic acids. Sarkar's 2025 review explicitly frames the ganoderic acids as the primary compounds responsible for Reishi's adaptogenic and hepatoprotective reputation in Chinese medicine.[3] The Wang 2024 five-year synthesis confirms hepatoprotective activity as one of the consistently documented properties across recent research.[6]
For a detailed look at how Reishi triterpenes specifically relate to cardiovascular and arterial health, see How Reishi Triterpenes Protect Against Arterial Plaque Buildup.
Where Ganoderic Acids Are Found in the Mushroom
Not all parts of the Reishi mushroom contain equal concentrations of ganoderic acids.
The fruiting body — the hard, woody structure that is the traditional medicinal form of Reishi — is the standard reference material for most ganoderic acid research. The 2025 TCM pharmacology review by Sarkar notes explicitly that mycelium has significantly less triterpenoid content than the fruiting body.[3] This creates a direct quality implication: supplements made from mycelium grown on grain substrates, which is a cheaper and faster production method, will typically contain substantially lower ganoderic acid levels than fruiting body products.
The most concentrated ganoderic acid source per gram of material is not the fruiting body but the spore powder. Ganoderma spores are released in enormous quantities during the mushroom's reproductive cycle, and a 2016 review by Soccol and colleagues confirmed that spore powder contains a higher density of ganoderic acids than fruiting body tissue per unit weight.[9] However, spores are enclosed within a tough outer wall called the sporoderm, which is not digestible by humans. Intact spores pass through the digestive system largely without releasing their contents.
A 2017 study by Wang and colleagues addressed this directly, testing combined chemical and physical methods to break the sporoderm wall and release the bioactives.[10] The study found that untreated intact spores had low bioavailability, while the sporoderm-broken preparations showed substantially higher triterpene release. Products marketed as "spore-wall-broken" or "cracked-cell Reishi spore powder" use this principle. The sporoderm-breaking step is not cosmetic — it is a functional prerequisite for bioavailability from spore-based products.
The Product Quality Problem: 57.9% of US Supplements Had No Detectable Triterpenes
In 2017, Wu and colleagues published a quality analysis of 19 commercial Ganoderma lucidum dietary supplements purchased from US retail and online markets.[11]
The results were striking. Triterpenes were detectable in only 8 of the 19 products: 42.1% of the sample. The remaining 11 products, 57.9% of those tested, had no measurable triterpene content. For beta-glucans, the rate was even worse: active 1,3-β-D-glucan was detectable in only 5 of the 19 products (26.3%).
Several factors produce this outcome. Products made from mycelium grown on starch-based grain substrates contain the grain substrate in the final product, diluting mushroom content substantially. Hot-water-only extraction produces products rich in water-soluble compounds (beta-glucans, polysaccharides) but without the fat-soluble triterpenes. Products that use low-quality dried mushroom powder without extraction may have more intact cell walls than accessible bioactives.
The Wu 2017 finding predates several tightening quality standards in the industry, but there is no systematic post-2017 quality audit data indicating widespread improvement. The structural problem, that triterpene content is not a required labeling disclosure and is not universally tested, remains.
For buyers, the Wu 2017 data suggests that the burden of verification is on the purchaser. Supplements that report triterpene content as a measured percentage (not just "contains Ganoderma extract"), that use alcohol extraction or dual extraction, and that are derived from mature fruiting bodies or properly processed spores, are more likely to contain actual ganoderic acids in meaningful amounts.
Why Hot Water Extraction Alone Does Not Produce Ganoderic Acids
Ganoderic acids are fat-soluble compounds, not water-soluble. The lanostane skeleton that all ganoderic acids share is structurally similar to cholesterol, a well-known fat-soluble molecule. Like cholesterol, ganoderic acids dissolve in alcohol and oils but not in water.
A 2025 review of Ganoderma bioactive components by Ren and colleagues stated this explicitly: triterpenoids activate steroid hormone receptor pathways, a mechanism that requires fat-solubility and the ability to enter cells directly, while polysaccharides act via Dectin-1/TLR pattern recognition receptors on the cell surface.[8] The two compound classes require different extraction conditions because their physical chemistry is fundamentally different.
Hot water extraction, including traditional Reishi tea preparation, releases the water-soluble compounds, primarily beta-glucans and polysaccharides. It does not release ganoderic acids. Alcohol extraction, typically using ethanol at 60–80% concentration, releases the triterpenes. Dual extraction, a process that uses both hot water and alcohol stages and combines the outputs, is required to produce a supplement containing both compound classes.
For a full technical explanation of how double extraction works and what it captures, see Double-Extraction Mushroom Tinctures: Why Alcohol + Water Captures More Compounds. For a comparison of product formats by compound delivery, see Hot Water Extract vs. Dual Extract vs. Raw Powder: Which Delivers More Beta-Glucans?.
The Bottom Line
Ganoderic acids are over 150 named lanostane triterpenes found only in Ganoderma species, with 495 total triterpenoids catalogued across 25 species as of 2022. They act through direct NF-κB and AP-1 suppression, distinct from the immune-cell-activation mechanism of beta-glucans. A 2026 PROSPERO-registered meta-analysis confirms consistent preclinical anti-inflammatory evidence, while individual studies demonstrate anti-cancer, hepatoprotective, and cardiovascular effects — most in cell-culture or animal models. A critical quality problem exists in the commercial market: in 2017, triterpenes were undetectable in 57.9% of US Ganoderma supplements tested, reflecting the structural problem that hot-water extraction produces no ganoderic acids and many products use mycelium rather than fruiting body.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.
- 9. Source details for this reference are not yet available.
- 10. Source details for this reference are not yet available.
- 11. Source details for this reference are not yet available.
- 12. Source details for this reference are not yet available.